BOSTON SCIENTIFIC CORP
Boston Scientific (BSX) is a global medical‑devices company with a market capitalisation of about $148.03bn, selling products used in cardiology, rhythm management, peripheral interventions, endoscopy and urology. Investors should know it earns recurring revenue from disposable devices and procedure-driven demand, backed by ongoing R&D and product launches. The business benefits from demographic trends such as an ageing population and wider access to minimally invasive therapies, yet it faces stiff competition from large peers, reimbursement and regulatory pressures, and occasional product or legal setbacks. Financial performance can be influenced by procedure volumes, hospital capital spending, foreign exchange and the success of new technologies. For investors, Boston Scientific offers exposure to healthcare innovation but also to sector-specific operational and regulatory risks. This is general educational information, not personalised advice — values can rise and fall and past performance is not a reliable guide to future returns.
Why It's Moving
Boston Scientific’s upbeat analyst setup keeps BSX in focus as investors lean into its growth story.
- Analysts continue to describe Boston Scientific as a strong large-cap medtech growth name, with the latest commentary pointing to broad conviction in its franchise and cash-generation profile.
- Recent target and rating updates have kept sentiment constructive, suggesting investors are looking past short-term price swings and focusing on the company’s longer-term revenue and profit trajectory.
- The stock is also benefiting from the broader medical-device backdrop, where steady procedure demand and defensive healthcare spending are supporting valuation interest in quality growth names.
Boston Scientific’s upbeat analyst setup keeps BSX in focus as investors lean into its growth story.
- Analysts continue to describe Boston Scientific as a strong large-cap medtech growth name, with the latest commentary pointing to broad conviction in its franchise and cash-generation profile.
- Recent target and rating updates have kept sentiment constructive, suggesting investors are looking past short-term price swings and focusing on the company’s longer-term revenue and profit trajectory.
- The stock is also benefiting from the broader medical-device backdrop, where steady procedure demand and defensive healthcare spending are supporting valuation interest in quality growth names.
When is the next earnings date for BOSTON SCIENTIFIC CORP (BSX)?
Boston Scientific's most recent Q1 2026 earnings were reported on April 22, 2026. The next earnings release, covering Q2 2026, is estimated between July 22 and July 27, 2026, based on the company's historical quarterly pattern, though no official date has been announced. Investors should monitor for updates as the window approaches.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Boston Scientific's stock with a target price of $125.38, indicating strong growth potential.
Financial Health
Boston Scientific is performing well with strong profits and cash flow, indicating solid business health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring BSX
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketStagflation Standouts
This collection features stocks and assets carefully selected by professional analysts to potentially outperform during stagflation periods. These defensive investments have already shown strength while the broader market struggles, making them worth consideration for economic uncertainty ahead.
Published: May 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Procedure demand tailwind
An ageing population and rising access to minimally invasive procedures can support long‑term demand, though volumes can ebb with hospital spending cycles.
Innovation and R&D
Regular product launches and technological improvements drive share gains and pricing power, but new products must clear regulatory and commercial hurdles.
Regulatory and market risks
Exposure to reimbursement, recalls and litigation means performance can be volatile; investors should weigh potential returns against these sector‑specific risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
